Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study

Last updated: August 14, 2025
Sponsor: Fondation Hôpital Saint-Joseph
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Polycystic Ovarian Syndrome

Reproductive Health

Treatment

Thrombotic profile

Clinical Study ID

NCT06339567
671_Hemo-PCOS
  • Ages 18-35
  • Female

Study Summary

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of childbearing age. PCOS can be individualized into several phenotypes, taking into account in particular the presence of hyperandrogenism, insulin resistance and BMI. Hyperandrogenism and insulin resistance appear to be important factors in the development of cardiovascular cardiovascular disease. In addition, patients frequently use anti-androgenic and/or contraceptive treatments contraceptives, such as combined hormonal contraception (CHC), the use of which is associated with an increased cardiovascular and thrombo and venous thrombosis (VTE). A meta-analysis published in 2020 by Gariani et al.

based on three large studies, estimated the risk of VTE in women with PCOS after adjustment for obesity and hormone therapy. This risk was significantly higher compared with women without PCOS (pooled OR 1.89, CI95% 1.60-2.24). No study has looked specifically investigated the risk of VTE according to different PCOS phenotypes. Such data would be very useful in clinical practice, as it would enable monitoring, contraceptive treatment and anti-androgenic anti-androgen treatment according to the PCOS phenotype, while limiting risks. Assessing the differences PCOS phenotypes is limited by the large sample size required. required. VTE is a rare event in women of childbearing age, and the number of PCOS phenotypes is high.

PCOS phenotypes. Intermediate markers of VTE risk are used in these situations. These markers are thrombin generation tests (notably ETP) and their sensitivity to activated protein C (nAPCsr) and thrombomodulin (nTMsr), as well as sex-hormone binding globulin (SHBG).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Be between 18 and 35 years of age at the time of inclusion;

  • Able to give non-opposition

  • Strong suspicion of PCOS according to 2023 recommendations

  • Have stopped hormonal contraception for at least 3 months or insulin-sensitizingtreatment for at least 3 months.

  • Fasting for at least 12 hours.

  • Be affiliated to a health insurance scheme.

  • French-speaking

Exclusion

Exclusion Criteria:

  • Already included in a type 1 interventional research protocol (RIPH1).

  • Be under guardianship or curatorship

  • Deprived of liberty

  • Under court protection

  • Pregnant (positive urine or blood pregnancy test), or within 3 months of post-partumor post abortum, or breastfeeding (or within 3 months of weaning)

  • Using hormonal contraception or insulin-sensitizing therapy (a wash-out of at least 3 months before inclusion).

  • Have a personal history of VTE or known thrombophilia.

  • Current anticoagulant or antiaggregant treatment or treatment stopped less than onemonth before inclusion.

  • Have a severe personal medical history in the previous 6 weeks (fracture, infection,hospitalization, surgery, cardiovascular event, cancer).

Study Design

Total Participants: 352
Treatment Group(s): 1
Primary Treatment: Thrombotic profile
Phase:
Study Start date:
February 08, 2024
Estimated Completion Date:
February 07, 2029

Connect with a study center

  • Hôpital Paris Saint Joseph

    Paris,
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.